The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Legal
  • Event

Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO
The PennZone/10289596

Trending...
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • Mister Omaha Tries The Turf At Lone Star Park
PHILADELPHIA, Dec. 4, 2024 ~ Franklin Biolabs, a newly established contract research organization (CRO) focused on genetic medicines, has announced the appointment of Vatsala Naageshwaran, PhD, as its Chief Executive Officer. The company was founded by renowned gene therapy pioneer, James Wilson, MD, PhD.

Dr. Naageshwaran brings over 20 years of experience in the biopharmaceutical industry to her new role at Franklin Biolabs. She is a highly accomplished executive with a strong commitment to advancing advanced therapies for patients. Throughout her career, she has successfully led cross-functional teams and delivered significant revenues to support business growth.

"We are thrilled to have Vatsala join our team at Franklin Biolabs," said Dr. Wilson, Chairperson of the company. "Her exceptional combination of business acumen and technical scientific expertise will be invaluable as we continue to grow and bring transformative therapies to patients with rare and debilitating diseases."

More on The PennZone
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • Destination Niagara Launches Game Changing Digital Magazine Redefining How Visitors Experience Niagara Falls
  • Val Market is the New Frontier of the Online Marketplace
  • San Diego's newest marketing firm is boring on purpose — it's working
  • Arizona Christian Homeschools Launches Statewide Directory

Prior to joining Franklin Biolabs, Dr. Naageshwaran held various leadership positions at biotech companies such as Myriad Genetics and Astex Pharmaceuticals. She also served as the Chief Business Officer at Absorption Systems, a contract research organization based in Exton, PA. In this role, she was responsible for driving the global business strategy for integrated services supporting small molecules, medical devices, and cell and gene therapies.

Most recently, Dr. Naageshwaran was the Vice President and Head of Business Development for US CGT & Lab Services at Pharmaron – a global service provider supporting large pharmaceutical and biotech companies in developing cell and gene therapy products.

"I am honored to join Franklin Biolabs and be a part of their groundbreaking work in gene therapy and healthcare innovation," said Dr. Naageshwaran. "I am confident that my experience will contribute to the development of innovative therapeutics that will have a profound impact on patients' lives worldwide."

More on The PennZone
  • LKPFM Corporation Canada the importance
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It
  • Ten Ten Ten Announces Free Value-Based Care Playbook for Independent Primary Care Practices
  • Senco Home Services Expands Residential Construction Services
  • Ricci's Painting & Contracting Expands Home Transformation Services

Dr. Naageshwaran holds degrees in biochemistry and molecular biology from Mount Holyoke College and pharmacometrics from the University of Maryland, Baltimore. She also completed her doctoral work in pharmaceutical drug research through a joint program between the University of Helsinki and Eastern Finland.

Her expertise has been recognized by the FDA, as she has received IDIQ and BAA grants to study PK/PD of complex products. Under her leadership, Pharmaron's San Diego site was named a Top CRO from 2018-2021. In 2021, she was nominated for the San Diego Business Woman of the Year Award. Dr. Naageshwaran's research has been presented at national conferences such as Association for Research in Vision and Ophthalmology (ARVO), American Association of Pharmaceutical Scientists (AAPS), Science of Toxicology (SOT), and American Association for Cancer Research (AACR). She has also authored multiple publications submitted to peer-reviewed journals.

With Dr. Naageshwaran at the helm, Franklin Biolabs is poised to make significant strides in advancing genetic medicines and improving patient outcomes. Her leadership and expertise will undoubtedly play a crucial role in the company's success as it continues to bring innovative therapies to those in need.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
  • George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
  • Mister Omaha Tries The Turf At Lone Star Park
  • Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
  • Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • TURRENTINE: A Family Legacy United Through Music
  • Save 10 Percent Off Summer Stays at KeysCaribbean Resorts
  • CGI Announces Pre-Order Launch for New Integrated Behavioral Health Book
  • IDI Consulting Supports Crohn's & Colitis Foundation as Silver Sponsor for Pittsburgh Take Steps Walk
  • Prince George's County Students Now Have A Rare Opportunity In TV Film Production Career-readiness

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 167
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • A Foundational Claim in Human Secrecy Goes Public
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing

Similar on PennZone

  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • LKPFM Corporation Canada the importance
  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us